Dr. Leland Gershell
Recent Articles about Lexeo Therapeutics Inc.
Pharma Announces Faster Approval Pathway for Neurodegenerative Disease 10/09/2025
Lexeo Therapeutics Inc. (LXEO:NASDAQ) announces a faster approval pathway for LX2006 in Friedreich's ataxia (FA). Find out why two analysts believe the company is emerging as a leader in developing transformative gene therapies for rare cardiac and neurodegenerative diseases.
© 2025 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
